medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2007, Number 1

<< Back

Ann Hepatol 2007; 6 (1)

Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C

Contreras AM, Monteón FJ, Flores MR, Mendoza-Sánchez F, Ruiz I

Language: English
References: 20
Page: 70-73
PDF size: 180.47 Kb.


Text Extraction

Drug-related hepatotoxicity is more common in renal transplant (RT) recipients with chronic liver disease because drug metabolism is not as efficient in these individuals. We describe a long-term survivor (30 years) of renal transplantation with hepatitis C virus (HCV) and drug-related hepatotoxicity. Our patient, a 26-year-old male, developed uremic syndrome in May 1976 and received a renal allograft from a related, living donor with an identical human leukocyte antigen genotype in August 1976. Maintenance immunosuppression treatment consisted of azathioprine (AZA) and prednisone. In 1993, the patient tested negative for HCV antibody v1.0 (anti-HCV). In 2000, the patient had elevated aminotransferases, which was attributed to pravastatin treatment. Remission of this abnormality was achieved once pravastatin was discontinued. In 2003, the patient again exhibited elevated levels of aminotransferases and AZA-related hepatotoxicity was suspected; therefore, AZA was discontinued and treatment with mycophenolate mofetil was initiated, which led to normal aminotransferase levels. The patient tested positive for anti-HCV v3.0 and HCV RNA and a liver biopsy showed chronic hepatitis with moderate activity. Currently, the patient’s renal transplant and liver are functional. In conclusion, hepatotoxic drugs should be used with caution in renal transplant recipients and close monitoring of liver function in patients with chronic viral hepatitis is crucial.


REFERENCES

  1. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38(5): 919–34.

  2. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med 2004; 71(1): 58–62.

  3. Pol S, Cavalcanti R, Carnot F, Legendre C, Driss F, Chaix ML, Thervet E, et al. Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Transplantation 1996; 61(12): 1774–6.

  4. Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109[suppl III]: 50–7.

  5. Pol S, Debure A, Degott C, Carnot F, Legendre C, Brechot C, Kreis H. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335: 878–80.

  6. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343–53.

  7. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 2005; 5: 1452–61.

  8. Rao KV, Anderson WR. Liver disease after renal transplantation. Am J Kidney Dis 1992; 19(5): 496–501.

  9. Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66(4): 471–6.

  10. Contreras AM, Chung RT. Hepatitis C virus in solid organ transplantation: not always a bad thing? Gastroenterology 2002; 123(5): 1729–33.

  11. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42(4): 631–57.

  12. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129–33.

  13. Perez RM, Ferreira AS, Medina-Pestana JO, Cendoroglo-Neto M, Lanzoni VP, Silva AE, Ferraz ML. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol 2006; 40(5): 444–8.

  14. Monteon FJ, Gomez B, Valdespino C, Chavez S, Sandoval M, Flores A, Herrera R, et al. The kidney transplant experience at Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara México. In: Cecka JM, Terasaki P, eds. Clinical Transplants 2003. UCLA Immunogenetics Center, Los Angeles: UCLA Immunogenetics Center, 2003: 165–74.

  15. Einollahi B, Hajarizadeh B, Bakhtiari S, Lesanpezeshki M, Reza-Khatami M, Hossein-Nourbala M, Pourfarziani V, et al. Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. J Gastroen Hepatol 2003; 18(7): 836–40.

  16. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47(No. RR-19): 1.

  17. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331(6): 365–76.

  18. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz WH. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clinical Transplant 2002; 16(2): 130–6.

  19. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001; 72(2): 241–4.

  20. Monteón FJ, Contreras AM, Espinoza L, Vazquez G, Aguilar S, Cueva L. Interferon Alfa-2b in renal transplant recipients with viral chronic hepatitis: A pilot study. Transplant Proc 1996; 28(6): 3306–08.




2020     |     www.medigraphic.com